沃森生物 (300142)

Walvax Biotechnology Co.,Ltd.

ASZ

Tags

Low Safety ScoreInnovative DrugsPharmaceutical ManufacturingSynthetic BiologyBiological VaccinesDispersed ShareholdingMargin Trading and Securities LendingChiNext 300 IndexChiNext IndexChiNext Blue ChipChiNext HealthcareChiNext TechSZSE 300 IndexTech 100 Index

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 159934.85
  • Circulating A-Shares(W): 155594.45
  • Earnings Per Share(RMB): 0.1022
  • Net Assets Per Share(RMB): 6.0545
  • Operating Revenue(W RMB): 171880.79
  • Total Profit(W RMB): 13627.86
  • Net Profit Attributable to Parent(W RMB): 16344.29
  • Net Profit Growth Rate(%): -36.24
  • Weighted Return on Equity(%): 1.7200
  • Operating Cash Flow Per Share(RMB): 0.0500
  • Undistributed Profit Per Share(RMB): 1.9861
  • Capital Reserve Per Share(RMB): 2.8442

2. Main Business

The main business covers:

  • Research, development, production, and sales of human vaccines

3. Company Basic Information

  • Company Name: Walvax Biotechnology Co., Ltd.
  • Listing Date: 2010-11-12
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 395 Kexin Road, High-tech Zone, Kunming City, Yunnan Province
  • Website: www.walvax.com
  • Company Profile：The Company was established through the overall change of Walvax Biotechnology Co., Ltd. On June 23, 2009, with the unanimous consent of all shareholders of Walvax Biotechnology Co., Ltd., based on the audited net asset value of RMB 77,626,523.60 as of May 31, 2009 by ShineWing Certified Public Accountants, 75 million shares were converted, and the remaining RMB 2,626,523.60 was included in capital reserve, thus establishing Walvax Biotechnology as a joint-stock company with a registered capital of RMB 75 million. The capital contribution for this overall change was verified by ShineWing Certified Public Accountants in the “XYZH/2007SZA2032-2” Capital Verification Report. On June 25, 2009, the Company obtained the amended business license from the Yunnan Provincial Administration for Industry and Commerce.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 E Fund ChiNext Board ETF Fund 3447.14 2.22
2 Chengdu Xiyun Enterprise Management Partnership (Limited Partnership) General Legal Person 2365.68 1.52
3 CSI 500 ETF Fund 2328.21 1.50
4 China Merchants Guozheng Biopharmaceutical Index Securities Investment Fund (LOF) Class A Fund 2306.78 1.48
5 Hong Kong Securities Clearing Company Ltd. Northbound Capital 2020.08 1.30
6 Harvest CSI Vaccine and Biotechnology ETF Fund 134.62 0.09
7 ChinaAMC Guozheng Vaccine and Biotech Index Initiation Securities Investment Fund Class A Fund 73.91 0.05
8 Penghua Guozheng Vaccine and Biotech ETF Fund 58.13 0.04
9 Guotai Guozheng Vaccine and Biotech ETF Fund 26.07 0.02
10 China Merchants CSI Vaccine and Biotechnology ETF Fund 11.90 0.01

5. Concept Sectors

  • Biological Vaccine
  • Innovative Drug
  • Synthetic Biology
  • Margin Trading & Securities Lending
  • Dispersed Shareholding
  • Low Safety Score
  • ChiNext Index
  • SZSE 300 Index
  • Technology 100 Index
  • ChiNext 300 Index
  • ChiNext Blue Chip Index
  • ChiNext Technology Index
  • ChiNext Pharmaceutical Index

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information